Syndivia and TVM Capital Life Science Announce Creation of Auricula Biosciences to Develop Innovative Therapy for Patients with K-Ras mutant malignancies

Written By Syndivia

LUXEMBOURG – January 13, 2022 – TVM Life Science Innovation II SCSp announced the Fund’s investment establishing Auricula Biosciences, Inc., a company based in Wilmington, Delaware, USA.

Auricula Biosciences plans to develop a first-in-class targeted therapeutic for a broad set of K-Ras mutant malignancies to clinical proof-of-concept. This conjugate targets macropinocytosis, a unique feature of cancer cells harboring K-Ras mutations.

Full press release is available at TVM Capital.

Syndivia https://syndivia.com
Previous

Renowned Nobel Laureate Jean-Marie Lehn Appointed Chairman of Syndivia's Scientific Advisory Board
Next

Syndivia Receives €2M Deeptech Financing From Bpifrance to Advance Its Lead Immunoconjugate for Solid Cancers